Medicine overview
Indications of Nepofer
Nepofer is an iron replacement product used specifically in patients undergoing maintenance hemodialysis.
Established / FDA-approved use
- Maintenance of hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD) who are receiving hemodialysis three times weekly.
Not indicated for
- Patients with non-dialysis-dependent chronic kidney disease.
- Patients on peritoneal dialysis or home hemodialysis (safety and efficacy not established in these settings).
Nepofer is not used to treat acute, severe iron-deficiency anemia unrelated to hemodialysis, and it is not a substitute for other iron replacement therapies in non-dialysis settings.
Composition
Each formulation of Ferric Pyrophosphate Citrate supplies elemental iron(III) in a soluble, low-molecular-weight complex form:
- As an intravenous solution: single-use ampules containing iron at a concentration of 1.5 mg/mL, delivering 6.75 mg of iron per ampule.
- As a hemodialysate concentrate additive: a formulation designed to be mixed into bicarbonate dialysate concentrate so that the final dialysate delivers approximately 2 mcg/mL of iron during the dialysis session.
No preservatives that are unsafe for the intended parenteral or dialysate route are included.
Description
Nepofer is a water-soluble, iron(III)-containing complex developed specifically for patients with hemodialysis-dependent chronic kidney disease. Unlike conventional intravenous iron products that are taken up by the reticuloendothelial system and slowly released, Nepofer is designed to donate iron directly to circulating transferrin, mimicking physiologic iron turnover.
It is administered either as a continuous low-dose infusion added to the bicarbonate dialysate used during each hemodialysis session, or as a separate intravenous solution (delivered pre- or post-dialyzer) during the dialysis session, replacing the ongoing iron losses that occur with routine hemodialysis.
Therapeutic Class
Nepofer belongs to the class of parenteral iron replacement agents (hematinics) formulated specifically for use in the hemodialysis setting.
Pharmacology
Mechanism
Ferric Pyrophosphate Citrate releases soluble iron(III) that binds directly to transferrin in the blood, bypassing the need for uptake, processing, and slow release by macrophages of the reticuloendothelial system, which is the typical pathway for conventional intravenous iron products.
Pharmacokinetics
Iron delivered as Ferric Pyrophosphate Citrate is incorporated into developing erythrocytes and appears in hemoglobin within days, replacing the iron lost during the hemodialysis procedure (from blood sampling, occult gastrointestinal loss, and residual blood in the dialysis circuit). Because delivery is continuous and matched to physiologic need, the risk of transient free (non-transferrin-bound) iron is reduced compared with bolus intravenous iron dosing.
Dosage & Administration of Nepofer
Adult dose (hemodialysis-dependent CKD)
| Formulation | Dose | Frequency |
|---|---|---|
| Intravenous solution | 6.75 mg iron | Once per hemodialysis session, infused over 3 to 4 hours via the pre-dialyzer or post-dialyzer line, three times weekly |
| Hemodialysate concentrate additive | Approximately 2 mcg/mL iron in final dialysate | Continuously throughout each hemodialysis session, three times weekly |
Pediatric dose
Safety and efficacy of Nepofer have not been established in pediatric patients; no pediatric dose is established (see Use in Special Populations).
Renal/hepatic adjustment
Nepofer is specifically indicated for patients already dependent on hemodialysis; no separate renal dose adjustment applies, and it is not indicated in patients with non-dialysis-dependent chronic kidney disease. No dedicated hepatic dose adjustment has been established.
Administer using aseptic technique; use a single-use ampule/solution only once and discard any unused portion.
Administration of Nepofer
Nepofer is administered only in a hemodialysis facility under medical supervision, using one of the following routes:
- Intravenous route: infused slowly via the pre-dialyzer or post-dialyzer blood line over 3 to 4 hours during hemodialysis.
- Dialysate route: added to bicarbonate concentrate before dialysate preparation so that iron is delivered continuously through the dialysate across the dialyzer membrane during the hemodialysis session.
Nepofer must not be administered by rapid intravenous push, and must not be self-administered.
Interaction of Nepofer
In vitro testing has shown that Nepofer does not affect the pharmacodynamic activity of heparin or low-molecular-weight heparins used during dialysis.
Concurrent administration with other intravenous iron products should be avoided, as this may increase the risk of iron overload; iron studies should guide any additional iron supplementation (see Precautions and Warnings for hypersensitivity risk shared across parenteral iron products).
Oral iron absorption may be reduced during the period when Nepofer raises circulating iron/transferrin saturation, so routine oral iron supplementation is generally unnecessary while receiving Nepofer.
Contraindications
Ferric Pyrophosphate Citrate is contraindicated in:
- Patients with known hypersensitivity to Ferric Pyrophosphate Citrate or any component of the formulation.
- Patients with evidence of iron overload (e.g., hereditary hemochromatosis or other iron overload syndromes).
Side Effects of Nepofer
The most commonly reported adverse reactions with Nepofer (occurring in ≥3% of patients) include:
- Headache
- Peripheral or generalized edema
- Asthenia/weakness and fatigue
- Vascular access complications (e.g., fistula/graft site problems)
- Urinary tract infection
- Pyrexia (fever)
- Procedural hypotension
- Muscle spasms and limb or back pain
- Dyspnea (breathing difficulty)
Serious hypersensitivity reactions, including anaphylaxis, have been reported rarely (see Precautions and Warnings).
Pregnancy & Lactation
Pregnancy: Data on the use of Nepofer in pregnant women are limited. Nepofer should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus; consult a physician before use.
Lactation: There is limited information on the presence of Nepofer in human milk or its effects on the breastfed infant. A physician should be consulted to weigh the benefits of treatment against any potential risk during breastfeeding.
Precautions & Warnings
Hypersensitivity reactions
Serious hypersensitivity reactions, including anaphylaxis, have been reported with parenteral iron products, including Nepofer; some have been life-threatening and fatal. Patients should be observed for signs and symptoms of hypersensitivity during and after each administration, in a facility equipped to manage anaphylaxis.
Hypotension
Hypotension can occur during hemodialysis sessions in which Nepofer is administered; blood pressure should be monitored as per routine dialysis practice.
Iron overload
Nepofer should not be used in patients with iron overload (see Contraindications). Periodic monitoring of iron parameters is recommended to avoid excessive iron accumulation with long-term use.
Restricted setting of use
Nepofer is intended only for adults with hemodialysis-dependent chronic kidney disease receiving in-center hemodialysis; it is not intended for patients on peritoneal dialysis, home hemodialysis, or non-dialysis-dependent chronic kidney disease.
Overdose Effects of Nepofer
Excessive administration of Nepofer could theoretically result in iron overload and its associated effects (e.g., elevated serum ferritin/transferrin saturation, and rarely, organ iron deposition with chronic excess). Because Nepofer is administered only under direct medical supervision in a hemodialysis facility, accidental overdose by patients is highly unlikely.
If overdose is suspected, seek immediate medical attention or contact emergency services/poison control. Management should be supportive and guided by a physician; do not attempt any specific home treatment.
Storage Conditions
Store ampules/solution protected from light in the original packaging (e.g., aluminum pouch) at controlled room temperature (20°C to 25°C); do not freeze. Keep out of reach of children. Discard any unused portion after single use.
Use In Special Populations
Renal impairment
Nepofer is specifically formulated for patients with hemodialysis-dependent chronic kidney disease; it is not indicated for non-dialysis-dependent CKD or peritoneal dialysis patients.
Hepatic impairment
No dedicated studies have established a need for dose adjustment in hepatic impairment.
Elderly
No overall differences in safety or effectiveness have been observed between elderly and younger adult patients in clinical trials of Nepofer.
Pediatric patients
Safety and efficacy of Nepofer have not been established in pediatric patients.
Duration Of Treatment
Nepofer is intended for ongoing, long-term use for as long as a patient remains dependent on in-center hemodialysis, administered at each dialysis session (typically three times weekly). The need for continued therapy should be reassessed periodically by the treating physician based on hemoglobin, serum ferritin, and transferrin saturation.
Reconstitution
For the hemodialysate concentrate formulation of Nepofer, the product is added to bicarbonate concentrate during preparation of the final dialysate, following the dialysis facility's standard aseptic mixing procedure, to achieve a final dialysate iron concentration of approximately 2 mcg/mL. The ready-to-use intravenous ampule formulation of Nepofer does not require reconstitution and should be used as supplied.
Drug Classes
Ferric Pyrophosphate Citrate is classified as a parenteral (intravenous/dialysate) iron replacement agent, also referred to as a hematinic used specifically in hemodialysis-dependent chronic kidney disease.
Mode Of Action
Ferric Pyrophosphate Citrate works by releasing soluble iron(III) that binds directly to transferrin in the bloodstream, delivering iron to erythroid precursor cells for incorporation into hemoglobin, without first requiring uptake and processing by the reticuloendothelial (macrophage) system as occurs with conventional intravenous iron products.
Pediatric Uses
The safety and efficacy of Nepofer have not been established in pediatric patients. Nepofer should not be used in children outside of a clinical trial setting until further data are available.
Frequently Asked Questions
Q: What is Nepofer 27.2 mg/5 ml IV Infusion used for?
A: Nepofer 27.2 mg/5 ml IV Infusion is an iron replacement product used to maintain hemoglobin levels in adults with hemodialysis-dependent chronic kidney disease who are receiving regular hemodialysis.
Q: How is Nepofer 27.2 mg/5 ml IV Infusion given?
A: Nepofer 27.2 mg/5 ml IV Infusion is given only in a hemodialysis facility, either as a slow intravenous infusion over 3 to 4 hours during each dialysis session, or continuously through the dialysate fluid during dialysis. It cannot be self-administered at home.
Q: Who should not receive Nepofer 27.2 mg/5 ml IV Infusion?
A: Nepofer 27.2 mg/5 ml IV Infusion should not be given to anyone with a known hypersensitivity to it or to patients who already have iron overload, such as those with hemochromatosis.
Q: What are the common side effects of Nepofer 27.2 mg/5 ml IV Infusion?
A: Common side effects include headache, swelling, weakness, fatigue, low blood pressure during dialysis, muscle spasms, and vascular access site problems. Serious allergic reactions are rare but can occur, so patients are monitored during and after each dose.
Q: Can Nepofer 27.2 mg/5 ml IV Infusion be used during pregnancy or breastfeeding?
A: Data are limited. Nepofer 27.2 mg/5 ml IV Infusion should be used in pregnancy only if clearly needed, weighing potential benefit against potential risk to the fetus, and a physician should be consulted regarding use during breastfeeding.
Q: Can Nepofer 27.2 mg/5 ml IV Infusion be used in children?
A: No. Safety and efficacy of Nepofer 27.2 mg/5 ml IV Infusion have not been established in pediatric patients, so it is not used in children outside of a clinical trial.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.
